tetano
Editor, Senior Moderator
ACS Nano
. 2024 Jun 27.
doi: 10.1021/acsnano.4c03075. Online ahead of print. A Nanoparticle Vaccine Displaying Conserved Epitopes of the Preexisting Neutralizing Antibody Confers Broad Protection against SARS-CoV-2 Variants
Xuefan Wu[SUP] 1 2 [/SUP], Wei Li[SUP] 1 [/SUP], Heng Rong[SUP] 1 2 [/SUP], Jingdi Pan[SUP] 1 2 [/SUP], Xiaowei Zhang[SUP] 1 [/SUP], Qinxue Hu[SUP] 1 [/SUP], Zheng-Li Shi[SUP] 1 [/SUP], Xian-En Zhang[SUP] 3 [/SUP], Zongqiang Cui[SUP] 1 2 [/SUP]
Affiliations
The rapid development of the SARS-CoV-2 vaccine has been used to prevent the spread of coronavirus 2019 (COVID-19). However, the ongoing and future pandemics caused by SARS-CoV-2 variants and mutations underscore the need for effective vaccines that provide broad-spectrum protection. Here, we developed a nanoparticle vaccine with broad protection against divergent SARS-CoV-2 variants. The corresponding conserved epitopes of the preexisting neutralizing (CePn) antibody were presented on a self-assembling Helicobacter pylori ferritin to generate the CePnF nanoparticle. Intranasal immunization of mice with CePnF nanoparticles induced robust humoral, cellular, and mucosal immune responses and a long-lasting immunity. The CePnF-induced antibodies exhibited cross-reactivity and neutralizing activity against different coronaviruses (CoVs). CePnF vaccination significantly inhibited the replication and pathology of SARS-CoV-2 Delta, WIV04, and Omicron strains in hACE2 transgenic mice and, thus, conferred broad protection against these SARS-CoV-2 variants. Our constructed nanovaccine targeting the conserved epitopes of the preexisting neutralizing antibodies can serve as a promising candidate for a universal SARS-CoV-2 vaccine.
Keywords: SARS-CoV-2; broad protection; conserved epitopes; nanovaccine; preexisting antibody.
. 2024 Jun 27.
doi: 10.1021/acsnano.4c03075. Online ahead of print. A Nanoparticle Vaccine Displaying Conserved Epitopes of the Preexisting Neutralizing Antibody Confers Broad Protection against SARS-CoV-2 Variants
Xuefan Wu[SUP] 1 2 [/SUP], Wei Li[SUP] 1 [/SUP], Heng Rong[SUP] 1 2 [/SUP], Jingdi Pan[SUP] 1 2 [/SUP], Xiaowei Zhang[SUP] 1 [/SUP], Qinxue Hu[SUP] 1 [/SUP], Zheng-Li Shi[SUP] 1 [/SUP], Xian-En Zhang[SUP] 3 [/SUP], Zongqiang Cui[SUP] 1 2 [/SUP]
Affiliations
- PMID: 38935412
- DOI: 10.1021/acsnano.4c03075
The rapid development of the SARS-CoV-2 vaccine has been used to prevent the spread of coronavirus 2019 (COVID-19). However, the ongoing and future pandemics caused by SARS-CoV-2 variants and mutations underscore the need for effective vaccines that provide broad-spectrum protection. Here, we developed a nanoparticle vaccine with broad protection against divergent SARS-CoV-2 variants. The corresponding conserved epitopes of the preexisting neutralizing (CePn) antibody were presented on a self-assembling Helicobacter pylori ferritin to generate the CePnF nanoparticle. Intranasal immunization of mice with CePnF nanoparticles induced robust humoral, cellular, and mucosal immune responses and a long-lasting immunity. The CePnF-induced antibodies exhibited cross-reactivity and neutralizing activity against different coronaviruses (CoVs). CePnF vaccination significantly inhibited the replication and pathology of SARS-CoV-2 Delta, WIV04, and Omicron strains in hACE2 transgenic mice and, thus, conferred broad protection against these SARS-CoV-2 variants. Our constructed nanovaccine targeting the conserved epitopes of the preexisting neutralizing antibodies can serve as a promising candidate for a universal SARS-CoV-2 vaccine.
Keywords: SARS-CoV-2; broad protection; conserved epitopes; nanovaccine; preexisting antibody.